Fulminant Herpes Simplex Hepatitis Secondary to Adalimumab in Crohn's Disease: A Case Report. Issue 12 (July 2019)

• Record Type: Journal Article
• Authors: Goel, Kanika; Bunker, Mark; Balog, Anna; Silverman, Jan F
• Is Part Of: Clinical medicine insights. Issue 12(2019)
• Publication Date: 2019-07
• Subjects: herpes simplex virus -- hepatitis -- inflammatory bowel disease -- TNF-α inhibitor -- Crohn's disease -- adalimumab; Clinical medicine -- Case studies -- Periodicals; Medicine; Clinical medicine; Electronic journals; Case Reports; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; Case studies; Periodicals; 616.09
• DOI: 10.1177/1179547619858979
• Languages: English
• ISSNs: 1179-5476

Abstract

Herpes simplex virus (HSV) hepatitis is an uncommon cause of fulminant hepatic failure, seen mostly in immunocompromised patients. Conventional treatment modalities for inflammatory bowel disease (IBD), such as steroids and azathioprine, have been known to cause HSV hepatitis. However, the reported incidence of HSV hepatitis in IBD patients undergoing tumor necrosis factor (TNF)-α inhibitor therapy is very rare. In this case report, we describe a rare case of fulminant HSV hepatitis that developed in a patient with Crohn's disease after treatment with the TNF-α inhibitor, adalimumab.